The quarter cleared a low bar by a wide margin. Published consensus was about $149.3 million of revenue and $0.11 of adjusted EPS; Azenta delivered $161.2 million and $0.16, a roughly $11.9 million revenue beat and $0.05 EPS beat. Both operating segments grew at double digits, rather than the prior quarter's weak backdrop carrying through. (Financial Highlights; Non-GAAP EPS reconciliation; Organic Revenue table)
| Metric | Q3 FY2026 actual | Q3 FY2025 | Prior quarter | Expectation / outlook change |
|---|---|---|---|---|
| Continuing-operations revenue | $161.2M | $143.9M | $144.8M | Published consensus: ~$149.3M (Income Statement) |
| Organic revenue growth | 9% | — | — | FY2026 outlook raised to flat to +1%, from -2% to +1% (Organic Revenue table; Outlook) |
| Non-GAAP diluted EPS, continuing operations | $0.16 | $0.17 | $(0.04) | Published consensus: ~$0.11 (Non-GAAP EPS reconciliation) |
| Adjusted EBITDA | $18.5M | $17.4M | $7.8M | Margin: 11.4% vs. 12.1% a year ago (Adjusted EBITDA reconciliation) |
| Adjusted gross margin | 46.2% | 47.6% | 44.3% | Down 140 bps year over year (Adjusted Gross Profit table) |
The guidance change is modestly better, not a wholesale reset. Full-year revenue was narrowed to $613–$618 million from $603–$621 million: the midpoint rises by $3.5 million, while the bigger signal is the organic-growth floor moving from a 2% decline to flat. That validates the quarter's rebound, but the company still expects low-single-digit sequential organic decline in Q4—so management is not declaring demand fully repaired. (Outlook)
Growth improved across both businesses, which makes the beat more credible. Sample Management revenue rose 14% year over year, including 9% organic growth, while Multiomics rose 10%, including 8% organically. Still, some weak pockets remain: Automated Stores and Sanger Sequencing declined, meaning the recovery is broadening but not yet uniform. (Segment revenue and organic-growth discussion)
Margins remain the limiting factor on the turnaround. Adjusted EBITDA rose 6% year over year, but adjusted gross margin fell 140 basis points because of lower-volume fixed-cost absorption and Automated Stores quality-remediation/rework costs. The quarter therefore beat expectations on sales and adjusted profit, while showing that conversion of that growth into sustainably better margins remains unfinished. (Adjusted EBITDA reconciliation; Adjusted Gross Profit table)
The headline GAAP profit should not be mistaken for core profitability. Total diluted EPS was $0.05, but continuing operations lost $0.03 per share; the positive total came from $0.09 per share in discontinued operations related to B Medical Systems, which was sold on July 1. The cleaner operating read is the $0.16 adjusted EPS from continuing operations. (Income Statement; Financial Highlights; Non-GAAP EPS reconciliation)
Balance-sheet capacity remains ample, though cash generation weakened. Cash plus marketable securities were about $522 million at June 30, while the company used $50.0 million for repurchases and generated $35.8 million of operating cash flow in the first nine months, down from $70.0 million a year earlier. That does not undermine the earnings beat, but it keeps attention on whether the improving revenue base translates into stronger cash conversion. (Balance Sheet; Cash Flow Statement)
Read the original 8-K on SEC EDGAR ↗